Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
September 5, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for August 9, 2005 Subscribe to this News Feed      
 

New Site for Free Vioxx Recall Information

The Vioxx Recall Site offers free Vioxx Recall Information and News 24/7 - updated daily.

(PRWEB) August 9, 2005 -- Given the monstrous size and profitability of drug companies, some plaintiff lawyers are considering focusing more of their practice on drug litigation. In fact, shortly after Merck's announcement of the Vioxx recall, some large plaintiff firms started aggressive media campaigns aimed at bringing in prescription drug injury victims. The media blitz has been non stop. Billboards, TV, Web marketing, radio, and direct mail are just some of the marketing vehicles that attorneys have used to try and find new cases for them to work on. Many plaintiff law firms are no longer focusing on chasing run of the mill car accidents. Some of them have gone so far as to reposition themselves as drug recall lawyers," seeing that the future of their practice may be shaped by the initial outcome of these new pharmaceutical cases.

When Merck chose to withdraw Vioxx, the CEO stated that a voluntary recall was the responsible course of action. Prior to pulling Vioxx from the market, Merck was spending $500 Million per year on advertising Vioxx. Vioxx is classified as a non-steroidal anti-inflammatory drug, or NSAID. However, Vioxx belongs to a new family of NSAIDs called COX-2 inhibitors." There are not many COX-2 inhibitors on the market in the US: Bextra and Celebrex may be the only other two.

Both the number of potential Vioxx plaintiffs and award amounts of the lawsuits are projected to be extremely large. The investment bank S.G. Cowan recently estimated that eventually more than 600,000 plaintiffs could file suit in the Vioxx case. Furthermore, some investment banks think that plaintiffs may file for more than $10Billion in damages in years to come. Even the national TV networks
have covered the Vioxx withdrawal. A November 2004 story on the Vioxx withdrawal appeared on CBS News' 60 Minutes. The CBS story implied that the US Justice Department is conducting an investigation and the Securities and Exchange Commission is looking into Merck's conduct. Given the media coverage of the Vioxx withdrawal and the number of people who were prescribed Vioxx, there may be many new Drug Recall Firms" founded in years to come.

About The Author
Richard Martin is a contributing writer at http://www.legalclips.com. LegalClips.com is a collection of lawyer articles and other resources.

You may reproduce this article on your Website. We would appreciate a link back to our site Legal Articles from you. This article may not be altered and links should be kept live. Thanks.

For more free articles, updates and information about the Vioxx recall and more, see: http://www.Vioxx-Recall-Site.com

Contact:
Jason Mangrum
931-233-1866
jason@nitromarketing.com

###

OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Jason Mangrum
931-233-1866
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright